Sodelglitazar
Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors. Safety Phase 2 studies were terminated prior to completion due to safety findings in rodent studies. See also * Elafibranor * GW0742 * GW501516 * MBX-8025 * Peroxisome proliferator-activated receptor In the field of molecular biology, the peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARs play essential roles in the regu ... References PPAR agonists Drugs developed by GSK plc Experimental drugs Trifluoromethyl compounds Fluoroarenes Thiazoles Carboxylic acids {{pharmacology-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]